The Biotech Voyager

Jeff Martin
  • 0.0（0則評分）
  • 新聞評論
  • 每日更新

Biotech's Live show. Dedicated to covering the early stage signals that indicate what's next in the industry.

  1. 3 天前

    The Kevin Walton Interview - Baseimmune

    Kevin Walton, CEO of Baseimmune, joins Ben and Jeff to break down one of the most underappreciated problems in modern medicine: fibrosis. IPF alone carries a life expectancy of three to five years upon diagnosis, and despite decades of research only three drugs have been approved, none of which halt or reverse the disease. Kevin explains why every previous approach has failed, why fibrosis is a network-driven redundant disease that defeats single-target therapies, and how Baseimmune's computational platform uses active immunotherapy to go after multiple pathways simultaneously with a single vaccine. Beyond fibrosis, Kevin reveals two additional applications the platform is being explored for, including a therapeutic vaccine for chronic pain and migraines, and a cardiovascular application. He also shares his take on what is most slept on in biotech right now: the immune system as a drug manufacturing platform. 0:00 Introduction 1:02 What is Baseimmune targeting with active immunotherapy 1:25 IPF — the disease, the stats, the failure of current drugs 1:49 Why single-target approaches keep failing 4:03 How the vaccine approach works 4:28 Additional applications beyond fibrosis 7:31 The data they've seen so far 9:35 Early results and what's encouraging 13:30 Pain vaccine — chronic migraines and the marketing opportunity 14:42 Cardiovascular applications 15:43 AI and the future of peptide-based immunotherapy 19:45 What's slept on in biotech — Kevin's answer 20:33 Immune system as a drug manufacturing platform 21:31 Jeff's response and closing thoughts New episodes every Tuesday and Thursday at 11:00 AM 🚀

    22 分鐘

  2. 6月26日

    Can You Turn Cancer Cells into Snitches? Plus Post-BIO Report

    Welcome to the Biotech Voyager. It's the live show that covers what's next in biotech. Feel free to leave a comment, and we will get to it as quickly as we can.

    1 小時 53 分鐘

  3. 6月24日

    The Jonathan Cohen-Gold Interview - CEO of Houdini Bio🧬

    Jonathan Cohen-Gold, CEO of Houdini Bio, joins Ben and Jeff to break down one of the most underappreciated problems in cell and gene therapy: cells don't like foreign DNA. When you deliver a therapeutic gene, the cell's innate immune system recognizes it as a threat and shuts it down. Houdini Bio's platform uses AI and proprietary Houdini elements, short 100 base pair sequences, to give the therapeutic DNA a self-hallmark, essentially camouflaging it against the cell's defense machinery without touching the pathway globally. The result is better transgene expression, safer delivery, and a plug-and-play approach that works across AAV, lentiviral, and other delivery formats. 0:00 Introduction 0:10 Welcome Jonathan Cohen-Gold, Houdini Bio 0:49 The problem: cells reject foreign DNA 1:39 Why this kills gene therapies 3:19 The market adoption crisis 4:42 Why previous approaches failed 5:11 The HUSH complex explained 6:15 Jonathan's PhD and unfair advantage 9:52 Building Houdini Bio from scratch 11:45 The Venture Science Doctorate 12:25 Academic system vs entrepreneurship 13:28 Houdini's platform and approach 14:00 Houdini elements explained 16:23 AI and the closed loop wet lab system 17:55 Current data and proof points 20:43 Rescuing failed gene therapies 22:18 What's next for Houdini Bio 25:22 The big opportunity 26:17 Investors and funding 29:19 Closing and what to watch for

    30 分鐘

  4. 6月24日

    Houdini Bio, TScan Ph3 & Bionyra $165M Series A

    Welcome to The Biotech Voyager. It's the show that covers what's next in biotech.

    1 小時 40 分鐘

  5. 6月20日

    No Investor Would Touch This. So They Built It Themselves

    Wesley Wierson and Alex Abel founded Leah Labs seven years ago around a pets-first model. When generative biology arrived, they designed something that no existing investor would fund. Animal investors won't back human-scale outcomes. Human investors won't back animal health companies. So VelociTx had to be built. Their CAR-T platform redesigns the transmembrane domain using a 2,000 de novo screen, finding 200 enriched candidates across 7 functional families, making CAR-T cells behave like TCR T cells to target solid tumors in ways nature never could. Wesley Wierson and Alex Abel are co-founders of VelociTx, a company using generative protein design to build the next generation of CAR-T cell therapy for solid tumors. Chapters 00:00:00 Welcome: Wesley Wierson + Alex Abel, VelociTx 00:00:58 Why VelociTx Had to Be Built 00:02:32 What If You Could Engineer a CAR Like a T Cell Receptor? 00:02:54 The Transmembrane Domain Discovery 00:06:34 The 2,000 De Novo Screen and What They Found 00:12:01 Going Into Lung Cancer First 00:15:51 How Generative Biology Changes Everything 00:27:35 What's Next in Biotech New episodes every Tuesday and Thursday at 11:00 AM 🚀

    31 分鐘

  6. 6月19日

    Why Do Some Patients' Cells Work and Others Don't?

    The biggest unsolved problem in cell therapy is donor variability. Why one patient's cells work and another's fail is a question the field still cannot answer. Alex Ward and Caelan Anderson, co-founders of Tolemy Bio, are building the intelligence layer that cell therapy has been missing. Their platform Orbit integrates all the process context around how cells are grown, managed, and manufactured to surface insights that nobody is currently leveraging. The goal is adaptive, patient-specific manufacturing across seventeen dimensions. Alex Ward and Caelan Anderson are co-founders of Tolemy Bio, a company building an AI-powered control panel for cell therapy manufacturing. Chapters 00:00:00 Welcome: Alex Ward + Caelan Anderson, Tolemy Bio 00:00:46 What Is Tolemy Bio and What Are They Building? 00:04:25 Why Do Some Patients' Cells Fail and Others Don't? 00:05:46 The Data Problem in Cell Therapy 00:14:00 The Control Panel for the Cell 00:15:15 Why Tolemy's Models Are Not Black Boxes 00:20:30 Adaptive Manufacturing Is the Future 00:25:34 What's Next in Biotech New episodes every Tuesday and Thursday at 11:00 AM 🚀

    30 分鐘

  7. 6月19日

    A Vaccine for Scar Tissue? And Cancer Cells that Build Their Own Destruction?

    Welcome to the Biotech Voyager. It's the live show that covers what's next in biotech. Today on the show: - 3 brand new startups in biotech that emerged from Stealth - 2 CEO interviews: one company is building a vaccine for tissue scarring, and the other, which just raised over $9M, turns solid tumors into therapeutic factories. Leave a comment if you have any questions - we try to get to them all!

    1 小時 52 分鐘

  8. 6月17日

    They 3D Printed a Kidney in Space? | Jana Stoudemire, Innovian Space | The Biotech Voyager

    This week, Innovian Space printed the first kidney and liver constructs in human history on the International Space Station. Jana Studemeier, CCO at Innovian Space, joins The Biotech Voyager to explain why gravity is the single biggest obstacle to printing functional organs, why microgravity solves it, and how the cost of a space experiment is nothing compared to the cost of a failed clinical trial. From Keytruda being reformulated using protein crystallization in space, to tumor organoids that behave more like real tumors in microgravity, to the coming explosion in regenerative medicine — this is the most unexpected biotech conversation we've had. Jana Studemeier is CCO at Innovian Space, a company helping organizations develop profitable and sustainable uses of space for biotech, pharma, and beyond. Chapters 00:00:00 Welcome: Jana Studemeier, Innovian Space 00:01:33 Printing Kidneys on the ISS This Week 00:03:10 Why Microgravity Changes Everything 00:06:26 Why 3D Printing Fails on Earth 00:10:23 Drug Testing With Tumor Organoids in Space 00:12:25 The Cost of Space vs Failing in Trials 00:19:18 Keytruda Was Reformulated Using Space 00:28:44 Space Will Cause a Regenerative Medicine Explosion New episodes every Tuesday and Thursday at 11:00 AM 🚀

    33 分鐘
顯示全部 (22)

簡介

Biotech's Live show. Dedicated to covering the early stage signals that indicate what's next in the industry.

資訊

  • 創作者
    Jeff Martin
  • 活躍年代
    2026年
  • 集數
    22
  • 年齡分級
    兒少適宜